Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • VT-122PC: Pilot trial data

    Vicus Therapeutics LLC, Morristown, N.J. Product: VT-122PC Business: Inflammation Molecular target: Adrenergic receptor beta (ADRB); Cyclooxygenase-2 (COX-2) Description: Fixed-dose combination of propranolol, a non-…

    Published on 1/26/2015
  • VX15/2503: Phase I data

    Vaccinex Inc., Rochester, N.Y. Product: VX15/2503 Business: Cancer Molecular target: Semaphorin 4D (SEMA4D) Description: Antibody against semaphorin 4D (SEMA4D) Indication: Treat advanced refractory solid tumors …

    Published on 1/26/2015
  • AG-348: Phase I final data

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-348 Business: Endocrine/Metabolic Molecular target: Pyruvate kinase R Description: Oral small molecule activator of pyruvate kinase R Indication: …

    Published on 1/19/2015
  • AG-348: Preliminary Phase I data

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-348 Business: Endocrine/Metabolic Molecular target: Pyruvate kinase R Description: Oral small molecule activator of pyruvate kinase R Indication: …

    Published on 1/19/2015
  • Brilinta: Phase III data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brilinta ( BriliqueEU) ticagrelor (AZD6140) Business: Cardiovascular Molecular target: Purinergic receptor P2Y…

    Published on 1/19/2015
  • DNA IL-12: Phase I data

    OncoSec Medical Inc. (OTCQB:ONCS), San Diego, Calif. Product: DNA IL-12 (OMS ElectroImmunotherapy, ImmunoPulse) Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: DNA plasmid coding for IL-12 …

    Published on 1/19/2015
  • Dutetrabenazine: Phase I data

    Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Product: Dutetrabenazine (SD-809) Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Deuterium-substituted …

    Published on 1/19/2015
  • Duvelisib: Development discontinued

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Duvelisib (IPI-145) (formerly INK-1197) Business: …

    Published on 1/19/2015
  • Eteplirsen: Additional Phase IIb data

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: Eteplirsen (AVI-4658) Business: Musculoskeletal Molecular target: DNA Description: Phosphorodiamidate morpholino oligomer (PMO) targeting exon 51 …

    Published on 1/19/2015
  • Gilenya fingolimod: Phase III data

    Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Gilenya fingolimod (FTY720) Business: Autoimmune Molecular target: Sphingosine 1-phosphate (S1P) …

    Published on 1/19/2015
  • Hemopurifier infectious data

    Aethlon Medical Inc. (OTCQB:AEMD), San Diego, Calif. Product: Hemopurifier Business: Infectious Molecular target: NA Description: Extracorporeal device that selectively absorbs viruses and immunosuppressive toxins from …

    Published on 1/19/2015
  • Ibrutinib: Additional Phase II data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Ibrutinib (Imbruvica) (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) …

    Published on 1/19/2015
  • IV delafloxacin: Phase III data

    Melinta Therapeutics Inc., New Haven, Conn. Product: IV delafloxacin (RX-3341) Business: Infectious Molecular target: DNA gyrase; Topoisomerase IV Description: Broad-spectrum fluoroquinolone antibiotic Indication: Treat…

    Published on 1/19/2015
  • IV finafloxacin: Phase II data

    MerLion Pharmaceuticals Pte. Ltd., Singapore Product: IV finafloxacin Business: Infectious Molecular target: DNA gyrase; Topoisomerase Description: IV formulation of a pH activated fluoroquinolone antibiotic Indication:…

    Published on 1/19/2015
  • Ixazomib: Phase II data

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Ixazomib (MLN9708) Business: Cancer Molecular target: Proteasome Description: Orally available proteasome inhibitor Indication: Treat newly diagnosed …

    Published on 1/19/2015
  • Migalastat: Phase III data

    Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Product: Migalastat (Amigal) (AT1001) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Small molecule that enhances alpha …

    Published on 1/19/2015
  • Opdivo nivolumab: Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 1/19/2015
  • Oral finafloxacin: Phase II data

    MerLion Pharmaceuticals Pte. Ltd., Singapore Product: Oral finafloxacin Business: Infectious Molecular target: DNA gyrase; Topoisomerase Description: Oral formulation of a pH activated fluoroquinolone antibiotic …

    Published on 1/19/2015
  • Pembrolizumab: Additional Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Pembrolizumab (Keytruda) (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PDCD1) (PD-1) (CD279) Description: …

    Published on 1/19/2015
  • PRM-151: Additional Phase II data

    Promedior Inc., Lexington, Mass. Product: PRM-151 Business: Hematology Molecular target: Serum amyloid P component (SAP) (APCS) Description: Recombinant version of pentraxin-2 (PTX-2), a human serum amyloid P component…

    Published on 1/19/2015
  • SAGE-547: Additional Phase I/II data

    Sage Therapeutics Inc. (NASDAQ:SAGE), Cambridge, Mass. Product: SAGE-547 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: Treat super-…

    Published on 1/19/2015
  • Testosterone undecanoate: Phase IIb data

    SOV Therapeutics Inc., Morrisville, N.C. Product: Testosterone undecanoate Business: Endocrine/Metabolic Molecular target: NA Description: Prodrug of testosterone Indication: Treat hypogonadism Endpoint: Proportion of …

    Published on 1/19/2015
  • Topsalysin: Interim Phase III data

    Sophiris Bio Inc. (NASDAQ:SPHS), La Jolla, Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Topsalysin (PORxin) (PRX302) (formerly PSA-PAH1) Business: Genitourinary Molecular target: …

    Published on 1/19/2015
  • Zubsolv buprenorphine/naloxone: Phase III data

    Orexo AB (SSE:ORX; OTCQX:ORXOY), Uppsala, Sweden Product: Zubsolv buprenorphine/naloxone (OX219) Business: Neurology Molecular target: NA Description: Sublingual tablet formulation of buprenorphine and naloxone …

    Published on 1/19/2015
  • ABX464: Phase I data

    Abivax S.A.S., Paris, France Product: ABX464 Business: Infectious Molecular target: NA Description: Small molecule inhibitor of HIV replication Indication: Treat HIV infection Endpoint: Safety and pharmacokinetics …

    Published on 1/12/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993